Loading patent…
AssigneeKawasaki Gakuen Educational Foundation
InventorsMikio Oka, Eiichi Nakayama, Yoshihiro Ohue, Koji Kurose
Estimating the term…
[Object] To provide a novel examination method for a cancer treatment effect, screening method for a peptide for a cancer vaccine, and peptide and composition for inducing an immune response against cancer. [Solving Means] Provided are an examination method for a cancer treatment effect and a screening method for a peptide for a cancer vaccine each including detecting an antibody against a cancer/testis antigen or an anti-p53 antibody in a sample. It is suitable that an anti-XAGE1 antibody (IgG and/or IgA) be detected, or an anti-NY-ESO-1 antibody (IgG) be detected. Also provided are a novel peptide and novel composition for inducing immune responses against cancer.
An examination method for prediction of effect of treatment of cancer for increased median survival time of overall survival or progression-free survival (PFS) over untreated subject in a subject suffering from cancer with immune checkpoint molecule inhibitor drug, comprising detecting antibody against a cancer/testis antigen in clinical samples, wherein the cancer/testis antigen is selected from the group consisting of XAGE1, NY-ESO-1, MAEL, BAGE, BORIS, MAGE-B3, and SSX4, wherein the detecting comprises detecting IgG-type antibody against the cancer/testis antigen, or IgG-type antibody against the cancer/testis antigen and IgA-type antibody against the cancer/testis antigen, wherein presence of IgG-type antibody is indicative of therapeutically effective condition for treatment with the checkpoint molecule inhibitor, and administering the checkpoint molecule inhibitor to the subject exhibiting positive anti-cancer/testis antigen antibody in the sample, wherein the immune checkpoint molecule is PD-1.
A method for treating a patient with an immune checkpoint molecule inhibitor drug, wherein the patient is suffering from cancer, the method comprising the steps of:
An examination method for prediction of effect of treatment of cancer for increased median survival time of overall survival or progression-free survival (PFS) over untreated subject in a subject suffering from cancer with immune checkpoint molecule inhibitor drug, comprising detecting antibody against a cancer/testis antigen in clinical samples, wherein the cancer/testis antigen is selected from the group consisting of XAGE1, NY-ESO-1, MAEL, BAGE, BORIS, MAGE-B3, and SSX4, wherein the detecting comprises detecting IgG-type antibody against the cancer/testis antigen, or IgG-type antibody against the cancer/testis antigen and IgA-type antibody against the cancer/testis antigen, wherein presence of IgG-type antibody is indicative of therapeutically effective condition for treatment with the checkpoint molecule inhibitor, and administering the checkpoint molecule inhibitor to the subject exhibiting positive anti-cancer/testis antigen antibody in the sample, wherein the detecting comprises detecting IgG-type antibody against the cancer/testis antigen and IgA-type antibody against the cancer/testis antigen, wherein positive IgG-type antibody and negative IgA-type is indicative of therapeutically effective condition.
An examination method for prediction of effect of treatment of cancer for increased median survival time of overall survival or progression-free survival (PFS) over untreated subject in a subject suffering from cancer with immune checkpoint molecule inhibitor drug, comprising detecting antibody against a cancer/testis antigen in clinical samples, wherein the cancer/testis antigen is selected from the group consisting of XAGE1, NY-ESO-1, MAEL, BAGE, BORIS, MAGE-B3, and SSX4, wherein the detecting comprises detecting IgG-type antibody against the cancer/testis antigen, or IgG-type antibody against the cancer/testis antigen and IgA-type antibody against the cancer/testis antigen, wherein presence of IgG-type antibody is indicative of therapeutically effective condition for treatment with the checkpoint molecule inhibitor, and administering the checkpoint molecule inhibitor to the subject exhibiting positive anti-cancer/testis antigen antibody in the sample, wherein the cancer/testis antigen is XAGE1.
Dependencies are inferred from the claim text.